A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
Public ClinicalTrials.gov record NCT01986933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
Study identification
- NCT ID
- NCT01986933
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Enrollment
- 264 participants
Conditions and interventions
Conditions
Interventions
- Placebo Other
- nemolizumab (CIM331) Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2013
- Primary completion
- Mar 31, 2015
- Completion
- May 31, 2016
- Last update posted
- Jan 24, 2022
2013 – 2016
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anniston | Alabama | 36207 | — |
| Not listed | San Diego | California | 92122 | — |
| Not listed | Miami | Florida | 33142 | — |
| Not listed | Alpharetta | Georgia | 30022 | — |
| Not listed | Arlington Heights | Illinois | 60005 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Indianapolis | Indiana | 46256 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Louisville | Kentucky | 40217 | — |
| Not listed | Bay City | Michigan | 48706 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Charlotte | North Carolina | 28226 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Charleston | South Carolina | 29407 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | College Station | Texas | 77845 | — |
| Not listed | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01986933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2022 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01986933 live on ClinicalTrials.gov.